JPWO2020011973A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020011973A5 JPWO2020011973A5 JP2020572642A JP2020572642A JPWO2020011973A5 JP WO2020011973 A5 JPWO2020011973 A5 JP WO2020011973A5 JP 2020572642 A JP2020572642 A JP 2020572642A JP 2020572642 A JP2020572642 A JP 2020572642A JP WO2020011973 A5 JPWO2020011973 A5 JP WO2020011973A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 80
- 108090001123 antibodies Proteins 0.000 claims 80
- 239000000427 antigen Substances 0.000 claims 59
- 102000038129 antigens Human genes 0.000 claims 59
- 108091007172 antigens Proteins 0.000 claims 59
- 150000007523 nucleic acids Chemical class 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 22
- 229920002676 Complementary DNA Polymers 0.000 claims 21
- 239000002299 complementary DNA Substances 0.000 claims 21
- 108020004707 nucleic acids Proteins 0.000 claims 14
- 230000004927 fusion Effects 0.000 claims 9
- NFGXHKASABOEEW-UHFFFAOYSA-N (+)-methoprene Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 7
- 230000002998 immunogenetic Effects 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 3
- 230000035693 Fab Effects 0.000 claims 3
- 108010094092 Glucocorticoid-Induced TNFR-Related Protein Proteins 0.000 claims 2
- 102000001009 Glucocorticoid-Induced TNFR-Related Protein Human genes 0.000 claims 2
- 102000004851 Immunoglobulin G Human genes 0.000 claims 2
- 108090001095 Immunoglobulin G Proteins 0.000 claims 2
- 229940027941 Immunoglobulin G Drugs 0.000 claims 2
- 102000009111 Inducible T-Cell Co-Stimulator Protein Human genes 0.000 claims 2
- 108010087868 Inducible T-Cell Co-Stimulator Protein Proteins 0.000 claims 2
- 102100017213 LAG3 Human genes 0.000 claims 2
- 108060004270 LAG3 Proteins 0.000 claims 2
- 210000004027 cells Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000006011 modification reaction Methods 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 101700056583 CD27 Proteins 0.000 claims 1
- 102100019459 CD27 Human genes 0.000 claims 1
- 102100007290 CD274 Human genes 0.000 claims 1
- 101710012053 CD274 Proteins 0.000 claims 1
- 210000000987 Immune System Anatomy 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710040448 TNFRSF4 Proteins 0.000 claims 1
- 102100013135 TNFRSF4 Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000003042 antagnostic Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000001472 cytotoxic Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1811403.3 | 2018-07-12 | ||
| GBGB1811403.3A GB201811403D0 (en) | 2018-07-12 | 2018-07-12 | Antibody molecules |
| PCT/EP2019/068804 WO2020011973A1 (fr) | 2018-07-12 | 2019-07-12 | Molécules d'anticorps |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021524478A JP2021524478A (ja) | 2021-09-13 |
| JPWO2020011973A5 true JPWO2020011973A5 (fr) | 2022-07-20 |
Family
ID=63273291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572642A Pending JP2021524478A (ja) | 2018-07-12 | 2019-07-12 | 抗体分子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210301022A1 (fr) |
| EP (1) | EP3820899A1 (fr) |
| JP (1) | JP2021524478A (fr) |
| AU (1) | AU2019303033A1 (fr) |
| CA (1) | CA3106002A1 (fr) |
| GB (1) | GB201811403D0 (fr) |
| TW (1) | TW202010756A (fr) |
| WO (1) | WO2020011973A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612520D0 (en) * | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| WO2019121906A1 (fr) | 2017-12-19 | 2019-06-27 | F-Star Beta Limited | Séquences de liaison spécifiques à pd-l1 insérées dans un domaine ch3 |
| EP4138888A1 (fr) * | 2020-04-23 | 2023-03-01 | Eli Lilly and Company | Absorption sous-cutanée et biodisponibilité d'anticorps |
| KR102534281B1 (ko) * | 2022-09-02 | 2023-05-30 | 한국생명공학연구원 | 신규한 항-pd-l1 키메릭 항원 수용체 및 이를 발현하는 면역세포 |
| CN116990528B (zh) * | 2023-09-27 | 2024-02-06 | 成都华西海圻医药科技有限公司 | 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| KR20220084444A (ko) | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| GB201500319D0 (en) * | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| EP3471754A1 (fr) * | 2016-06-20 | 2019-04-24 | Kymab Limited | Anticorps anti-pd-l1 |
| CA3027612A1 (fr) * | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Molecules de liaison liant pd-l1 et lag -3 |
| US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3487883B1 (fr) * | 2016-07-20 | 2023-01-04 | Stcube, Inc. | Méthodes de traitement et de thérapie du cancer utilisant une combinaison d'anticorps qui se lient à pd-l1 glycosylé |
-
2018
- 2018-07-12 GB GBGB1811403.3A patent/GB201811403D0/en not_active Ceased
-
2019
- 2019-07-12 EP EP19742154.8A patent/EP3820899A1/fr active Pending
- 2019-07-12 CA CA3106002A patent/CA3106002A1/fr active Pending
- 2019-07-12 US US17/259,642 patent/US20210301022A1/en active Pending
- 2019-07-12 AU AU2019303033A patent/AU2019303033A1/en active Pending
- 2019-07-12 WO PCT/EP2019/068804 patent/WO2020011973A1/fr unknown
- 2019-07-12 TW TW108124736A patent/TW202010756A/zh unknown
- 2019-07-12 JP JP2020572642A patent/JP2021524478A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11987635B2 (en) | Anti-4-1BB antibodies and methods of making and using thereof | |
| JP2022068161A (ja) | 新規抗ｐｄ－ｌ１抗体 | |
| JP6822849B2 (ja) | 多重特異的ＮＫｐ４６結合タンパク質 | |
| JP2020520665A5 (fr) | ||
| US20230212293A1 (en) | Pd-1 agonist multimeric binding molecules | |
| JPWO2019129221A5 (fr) | ||
| WO2021063349A1 (fr) | Anticorps ciblant bcma, anticorps bispécifique et leur utilisation | |
| CA3089230A1 (fr) | Proteines de liaison a un antigene trispecifiques | |
| CN110831973A (zh) | 多特异性抗体及其制备和使用方法 | |
| WO2020173378A1 (fr) | Anticorps se liant au gène lag -3 humain, son procédé de préparation et son utilisation | |
| CN116745317A (zh) | 抗tigit抗体及其用途 | |
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| TW202221041A (zh) | 一種結合人pd-l1的抗體 | |
| CA2875451A1 (fr) | Anticorps dirige contre un transporteur et son utilisation | |
| CN112480259B (zh) | 抗tnfr2抗体及其用途 | |
| KR20200132996A (ko) | 세포 연계 결합 분자 | |
| JPWO2020011973A5 (fr) | ||
| WO2022222530A1 (fr) | Anticorps anti-tigit et son utilisation | |
| US20240084026A1 (en) | Anti-4-1bb antibodies and methods of making and using thereof | |
| US20230086069A1 (en) | Anti-cd19 antibodies and methods of using and making thereof | |
| WO2023186063A1 (fr) | Anticorps anti-pvrig, composition pharmaceutique et utilisation associées | |
| AU2020257053B2 (en) | Cell engaging binding molecules | |
| CN115819582A (zh) | Pvrig的抗体或其抗原结合片段及其应用 | |
| CA3210910A1 (fr) | Anticorps anti-pd-l1 et son utilisation | |
| TW202333788A (zh) | 一種抗ｔｎｆｒ２抗體藥物組合物 |